AUPH — Aurinia Pharmaceuticals Inc.
$15.73
$-0.48 (-2.96%)
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Market Cap
$2.11B
Forward P/E
13.6x
52-Week Range
N/A
AUPH Price History
Revenue vs. Net Income
$283M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$135M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
16.2%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-5.1%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
